Continuous Glucose Monitoring Clinical Trial
Official title:
The Use of a Continuous Glucose Monitoring System (Dexcom G6) in Hospitalized Patients for Acute Care
The state of a coronavirus disease pandemic (COVID-19) was declared by the World Health Organization on March 11, 2020. Hospitalized patients receiving intravenous (IV) insulin therapy have been identified in the hospital setting as a group that places health care workers at high risk of contamination. Indeed, the many capillary blood glucose measurements required to adjust the IV insulin doses involve direct contact with the patient. It is generally recommended to measure blood sugar every 1 to 2 hours with an IV insulin infusion. Ensuring a working method allowing optimal monitoring of patients' blood sugar levels while limiting the risk of contamination of health professionals is therefore to be preferred. Continuous Glucose Monitoring (CGM) systems are minimally invasive devices that allow you to get a blood glucose measurement every 5 to 15 minutes, and some devices allow you to access your blood sugar profile without having to be in contact with the patients. These devices are approved, validated, and widely used in diabetic ambulatory populations. The principle is based on a measurement of glucose in the interstitial fluid under the skin. DEXCOM G6 is the only device currently approved in Canada that does not require calibration using a capillary blood glucose level or contact with the patient for remote data transmission. A sensor installed on the skin makes it possible to measure blood sugar from the interstitial fluid. A transmitter installed on the sensor sends the data to a receiver which can be remote from the patient (up to 6 meters). Its use in an acute care setting, however, is not approved in Canada. However, Health Canada issued an emergency order on April 25, 2020 allowing the use of Dexcom G6 in hospitals during the COVID-19 pandemic. The CGM offers several potential advantages compared to the capillary glycemia currently used to ensure the follow-up of insulin-treated patients thanks to the real-time measurement of the glycemia and their transmission at a distance. In intensive care the SGC has the potential: - For staff to limit contact with patients infected with COVID-19 (reduction in the use of personal protective equipment and contamination) while ensuring close monitoring of blood glucose levels for the adjustment of insulin therapy. - For patients to reduce the discomfort related to multiple capillary blood sugar levels and possibly better detection of hypoglycaemia This study is the first step in a 2-phase research program, the ultimate goal of which is to use a CGM to replace capillary blood glucose in hospitals to adjust intravenous (IV) insulin therapy. The objective of the first study presented in this protocol is to validate the use of a continuous glucose monitoring system (CGM) for glycemic monitoring in patients hospitalized in intensive care.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04099043 -
Cascade CGM 15-day Performance Assessment
|
N/A | |
| Recruiting |
NCT05441982 -
Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes
|
N/A | |
| Completed |
NCT05038761 -
A Study to Learn How Well a Monitoring System Called Continuous Glucose Monitoring (CGM) Which Measures Glucose on an Ongoing Basis Works and How Safe it is in Chinese Patients in Usual Practice
|
||
| Completed |
NCT01714895 -
Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring
|
N/A | |
| Not yet recruiting |
NCT05531838 -
Prediabetes Management
|
N/A | |
| Completed |
NCT04125160 -
Glycaemic Markers in Persons With Type 2 Diabetes on Peritoneal Dialysis
|
||
| Active, not recruiting |
NCT06226948 -
Using the Visualization for Lifestyle Change in Patients at Risk of Cardiovascular Diseases
|
N/A | |
| Completed |
NCT05348928 -
A Pilot Study of the Feasibility and Accuracy of the TrueVie CGM System - A Non-Significant Risk Study
|
||
| Active, not recruiting |
NCT05336214 -
Implementing Continuous Glucose Monitoring in Primary Care for Patients With Diabetes
|
N/A | |
| Terminated |
NCT03067480 -
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
|
N/A | |
| Completed |
NCT04558710 -
The Effect of Frequent Continuous Glucose Monitoring Use on Glucose Variability in Preschoolers With Type 1 Diabetes
|
||
| Not yet recruiting |
NCT06436326 -
The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes
|
N/A | |
| Not yet recruiting |
NCT04172116 -
Continuous Glucose Monitoring (CGM) After Surgical Variations of the Roux-en-y Gastric Bypass
|
||
| Completed |
NCT01883622 -
Glucose Variability in Pregnancy Complicated by Diabetes
|
N/A | |
| Recruiting |
NCT05947916 -
Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy
|
N/A | |
| Active, not recruiting |
NCT05564481 -
Research on Optimizing the Use of Technology With Education
|
N/A | |
| Recruiting |
NCT06400641 -
Study on the Feasibility of Continuous Glucose Monitoring(CGM) for Improving Blood Glucose Control in Severe Patients
|
||
| Recruiting |
NCT04099550 -
Effect of Real-time Continuous Glucose Monitoring System in Overweight or Obese Adults With Prediabetes
|
N/A | |
| Not yet recruiting |
NCT04397965 -
Cascade Continuous Glucose Monitor (CGM) 15-Day US Performance Assessment
|
N/A | |
| Completed |
NCT02942069 -
Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring
|